復宏漢霖-B(02696.HK)PD-1聯合治療新進展,上市次日收盤49.5港元
格隆匯9月26日丨復宏漢霖-B(02696.HK)宣佈,近日,公司重組抗PD-1人源化單克隆抗體注射液(HLX10)聯合重組抗VEGF人源化單克隆抗體注射液(HLX04)治療晚期肝細胞癌(HCC)的2期臨牀研究已完成首例患者給藥。
該項研究是在經標準治療後發生疾病進展或不可耐受毒性反應的晚期肝細胞癌患者中開展的一項單臂、開放、多中心的臨牀2期研究,旨在評估HLX10聯合HLX04在治療晚期肝細胞癌中的臨牀療效、安全性和耐受性。
公告稱,截至公告日,於中國境內尚無同類聯合用藥治療方案獲國家藥品監督管理局批准。
截止2019年9月26日,復宏漢霖-B(02696.HK)開盤價48.95港元,振幅3.03%,盤中創上市以來新高49.55港元,收盤價49.50港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.